Nordera G P, Lorizio A, Lion P, Durisotti C, D'Andrea G, Ferro-Milone F
Department of Neurology, Vicenza Hospital, Italy.
Eur Neurol. 1987;27 Suppl 1:76-80. doi: 10.1159/000116197.
Results obtained in 22 patients with Parkinson's disease in whom treatment with standard Madopar was replaced by Madopar HBS, a CR formulation of the same product, are presented. All the patients presented with dyskinesia and akinesia phenomena related in part to the L-dopa treatment and in part to the disease itself. In 20 patients replacement of the standard agent by HBS led to a distinct improvement in the clinical condition and a significant reduction of the 'on-off' phenomenon. However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar. In 6 of the 22 patients treatment with the HBS formulation has continued for over 6 months and is still giving very good results.
本文呈现了22例帕金森病患者的治疗结果。这些患者原本接受标准美多芭治疗，现改用同一产品的控释制剂美多芭HBS。所有患者均出现了运动障碍和运动不能现象，部分与左旋多巴治疗有关，部分与疾病本身有关。20例患者将标准制剂换为HBS后，临床状况明显改善，“开-关”现象显著减少。然而，与标准美多芭相比，使用新制剂时平均剂量必须增加86%。22例患者中有6例使用HBS制剂治疗已超过6个月，目前仍有非常好的效果。
